ATAD2

Across TCGA pan-cancer cohorts, ATAD2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATAD2 data layer compared with 23 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ATAD2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ATAD2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where ATAD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.741	0.924	.001	40	view →
LSCC	OS	Quartile	All	0.963	0.736	.009	31	view →
HNSC	OS	Median	All	0.804	0.906	.015	21	view →
LUAD	DFS	Median	II,III,IV	0.935	0.771	.015	6	view →
UCEC	OS	Quartile	II,III,IV	1.000	0.519	.042	4	view →
CCRCC	DFS	Median	All	1.000	0.860	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATAD2–PDAC (OS)

Open the PDAC breakdown →